Immuno-Oncology | Specialty

Dr. Choueiri on the Role of Cabozantinib in RCC

October 10th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer

October 10th 2017

The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.

Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer

October 6th 2017

Harry H. Yoon, MD discussed the promise of immunotherapy and emphasized the importance of mismatch repair deficiency testing in gastric/GEJ Cancer.

Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer

October 6th 2017

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

Dr. De Santis on the Future Treatment Landscape for Bladder Cancer

October 6th 2017

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma

October 5th 2017

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma

October 5th 2017

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

Atezolizumab + Bevacizumab in Treatment-Naive mRCC

October 4th 2017

Sunitinib Before Cytoreductive Nephrectomy in mRCC

October 4th 2017

CABOSUN: Upfront Use of Cabozantinib for mRCC

October 4th 2017

CheckMate-214: Nivolumab/Ipilimumab for mRCC?

October 4th 2017

Dr. Welling on the Efficacy of Nivolumab in HCC

October 4th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Emerging Data Show Promise With Immunotherapy Combos in NSCLC

October 3rd 2017

Jyoti D. Patel, MD, discusses ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.

Standard Biopsies Retain Significant Role in Lung Cancer Care

October 3rd 2017

Philip D. Bonomi, MD, discusses some of the known biomarkers in non-small cell lung cancer (NSCLC), the utilization of PD-L1, and other testing modalities.

Expert Highlights Biological Advancements in Bladder Cancer Field

October 3rd 2017

Brant Inman, MD, discusses the biology of bladder cancer, the evolving role of checkpoint inhibitors, and the future of chemotherapy in the disease.

HR+ Breast Cancer: Updated Results From MONARCH Trials

October 2nd 2017

Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017

HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017

Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017